Raising the Bar: Optimizing Outcomes With IL-23/IL-17 Inhibitors in Spondyloarthritis

Do you know what the consequences are of spondyloarthrtitis left untreated? Learn from our experts.    Credit available for this activity expires:  11/30/24  Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998875?ecd=bdc_podcast_libsyn_mscpedu